They Asked for it: Patient Request Fuels Brand-Name Preference

Published Online: Thursday, February 14, 2013
Follow Pharmacy_Times:
Physicians are more likely to prescribe a brand-name medicine if a patient requests it specifically, regardless of whether a generic alternative is available, according to researchers from Harvard University Medical School.

Study authors selected 2938 eligible physicians from a national survey that covered 7 care specialties, with 1891 of those eligible participating.

“Approximately 4 of 10 physicians report that they sometimes or often prescribe a brand name drug to a patient when a generic is available because the patient wanted it,” the study authors reported. “These numbers suggest that the unnecessary costs associated with this practice to the health care system could be substantial.”

The study, which was published online January 7, 2013, in JAMA Internal Medicine (formerly Archives of Internal Medicine), also determined that participants were more likely to accept free samples of brand-name drugs to give to patients.

An analysis of prescribing behavior determined that 43% of physicians practicing at least 30 years and 31% of physicians practicing for 10 years or less will sometimes or often issue a brand-name prescription if a patient requests the drug. Internal medicine physicians were more likely to consent to patient requests than pediatricians, anesthesiologists, cardiologists, and general surgeons, researchers determined. In addition, physicians working in a solo practice or with 1 other physician were more likely to fulfill a brand-name request than those working in hospitals or medical schools.

Authors noted several limitations to their findings, including whether a prescription was dispensed as written. Certain states allow for generic substitution when the medication is filled, and dispensing information was not monitored.

Industry-physician relationships influenced the inclination to fulfill brand-name drug requests as well, authors reported. Receiving free food and/or beverages and product samples from drug representatives made physicians more likely to agree to a brand-name drug request. Meeting with drug representatives for product or therapy updates also made physicians more likely to acquiesce to a request for brand-name medication.

The Generic Pharmaceutical Association (GPhA) focused on a portion of the study’s introduction that noted the higher copayments, increased insurance cost, and higher Medicare and Medicaid expenses seen when prescription drugs are used rather than available generics.

“The JAMA Internal Medicine study demonstrates that we are still leaving savings on the table that could be achieved by increasing the use of generic drugs,” Ralph G. Neas, president and chief executive officer of GPhA, said in a release.

The authors’ suggested interventions include a closed health care system, similar to the Veterans Health Administration or the system used in Britain, where the pharmacy has primary control over dispensation decisions. Alternate suggestions include prohibiting physicians from dispensing product samples and instead offering the samples at the pharmacy. The authors also mentioned banning physicians from accepting representative-provided food and beverages at work.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times